Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA

• Published in: Thrombosis and haemostasis Vol. 88; no. 4; p. 583
• Main Authors: Tripodi, Armando, Chantarangkul, Veena, Clerici, Marigrazia, Mannucci, Pier Mannuccio
• Format: Journal Article
• Language: English
• Published: Germany 01-10-2002
• Subjects: Administration, Oral; Anticoagulants - administration & dosage; Anticoagulants - pharmacology; Antiphospholipid Syndrome - blood; Antiphospholipid Syndrome - diagnosis; Antiphospholipid Syndrome - drug therapy; Blood Coagulation Tests - methods; Blood Coagulation Tests - standards; Case-Control Studies; Clinical Laboratory Techniques; Humans; Lupus Coagulation Inhibitor - blood; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reagent Kits, Diagnostic - standards; Silicon Dioxide
• ISSN: 0340-6245
• DOI: 10.1055/s-0037-1613259

The detection of lupus anticoagulant (LA) in plasmas from patients on oral anticoagulants is problematic because of their prolonged clotting times. Mixing of patients and normal plasmas prior to testing for LA is employed to overcome this problem. We investigated the diagnostic efficacy of silica clotting time (SCT) and dilute Russell viper venom test (dRVVT) performed at low and high phospholipid concentrations, to diagnose LA in patients on oral anticoagulants, in comparison with Staclot LA (Stago) performed with and without hexagonal phospholipids and normal plasma. Case materials were 114 filtered plasmas from patients on oral anticoagulants with (n = 62) and without (n = 52) the antiphospholipid syndrome. Plasmas were considered LA-positive when Staclot LA (taken as the "gold standard") was diagnostic for LA. Forty-four plasmas were positive with Staclot LA. Forty and 39 of these were also positive with SCT and dRVVT (sensitivity relative to Staclot LA was 91% and 89%, respectively). Seventy plasmas were negative with Staclot LA. Three of these were positive with both SCT and dRVVT (specificity relative to Staclot LA was 96%). Kappa values for measure of agreement were 0.87 and 0.85 (p <0.001), respectively. In conclusion, SCT and dRVVT performed at low and high phospholipid concentrations without normal plasma can be considered as reliable as Staclot LA performed with hexagonal phospholipids and normal plasma to diagnose LA in patients on oral anticoagulants. Advantages of SCT and Drvvt over Staclot LA are easy automation, no need for normal plasma and relatively low cost.